1
|
Yao K, Wang X, Li W, Zhu H, Jiang Y, Li Y, Tian T, Yang Z, Liu Q, Liu Q. Semi-supervised heterogeneous graph contrastive learning for drug-target interaction prediction. Comput Biol Med 2023; 163:107199. [PMID: 37421738 DOI: 10.1016/j.compbiomed.2023.107199] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 04/15/2023] [Accepted: 06/19/2023] [Indexed: 07/10/2023]
Abstract
Identification of drug-target interactions (DTIs) is an important step in drug discovery and drug repositioning. In recent years, graph-based methods have attracted great attention and show advantages on predicting potential DTIs. However, these methods face the problem that the known DTIs are very limited and expensive to obtain, which decreases the generalization ability of the methods. Self-supervised contrastive learning is independent of labeled DTIs, which can mitigate the impact of the problem. Therefore, we propose a framework SHGCL-DTI for predicting DTIs, which supplements the classical semi-supervised DTI prediction task with an auxiliary graph contrastive learning module. Specifically, we generate representations for the nodes through the neighbor view and meta-path view, and define positive and negative pairs to maximize the similarity between positive pairs from different views. Subsequently, SHGCL-DTI reconstructs the original heterogeneous network to predict the potential DTIs. The experiments on the public dataset show that SHGCL-DTI has significant improvement in different scenarios, compared with existing state-of-the-art methods. We also demonstrate that the contrastive learning module improves the prediction performance and generalization ability of SHGCL-DTI through ablation study. In addition, we have found several novel predicted DTIs supported by the biological literature. The data and source code are available at: https://github.com/TOJSSE-iData/SHGCL-DTI.
Collapse
Affiliation(s)
- Kainan Yao
- School of Software Engineering, Tongji University, 4800 Caoan Road, Jiading District, Shanghai, 201804, China
| | - Xiaowen Wang
- School of Software Engineering, Tongji University, 4800 Caoan Road, Jiading District, Shanghai, 201804, China
| | - Wannian Li
- Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Tongji University), Ministry of Education, Orthopaedic Department of Tongji Hospital, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, 1239 Siping Road, Yangpu District, Shanghai, 200092, China.
| | - Hongming Zhu
- School of Software Engineering, Tongji University, 4800 Caoan Road, Jiading District, Shanghai, 201804, China
| | - Yizhi Jiang
- School of Software Engineering, Tongji University, 4800 Caoan Road, Jiading District, Shanghai, 201804, China
| | - Yulong Li
- School of Software Engineering, Tongji University, 4800 Caoan Road, Jiading District, Shanghai, 201804, China
| | - Tongxuan Tian
- School of Software Engineering, Tongji University, 4800 Caoan Road, Jiading District, Shanghai, 201804, China
| | - Zhaoyi Yang
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, No. 96, JinZhai Road Baohe District, Hefei, 230001, Anhui, China.
| | - Qi Liu
- Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Tongji University), Ministry of Education, Orthopaedic Department of Tongji Hospital, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, 1239 Siping Road, Yangpu District, Shanghai, 200092, China.
| | - Qin Liu
- School of Software Engineering, Tongji University, 4800 Caoan Road, Jiading District, Shanghai, 201804, China.
| |
Collapse
|
2
|
Abstract
Spirocyclic scaffolds are incorporated in various approved drugs and drug candidates. The increasing interest in less planar bioactive compounds has given rise to the development of synthetic methodologies for the preparation of spirocyclic scaffolds. In this Perspective, we summarize the diverse synthetic routes to obtain spirocyclic systems. The impact of spirocycles on potency and selectivity, including the aspect of stereochemistry, is discussed. Furthermore, we examine the changes in physicochemical properties as well as in in vitro and in vivo ADME using selected studies that compare spirocyclic compounds to their nonspirocyclic counterparts. In conclusion, the value of spirocyclic scaffolds in medicinal chemistry is discussed.
Collapse
Affiliation(s)
- Kerstin Hiesinger
- Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue Straße 9, D-60348 Frankfurt am Main, Germany
| | - Dmitry Dar'in
- Institute of Chemistry, Saint Petersburg State University, 199034 Saint Petersburg, Russia
| | - Ewgenij Proschak
- Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue Straße 9, D-60348 Frankfurt am Main, Germany
| | - Mikhail Krasavin
- Institute of Chemistry, Saint Petersburg State University, 199034 Saint Petersburg, Russia
| |
Collapse
|
3
|
Martinez-Alsina LA, Murray JC, Buzon LM, Bundesmann MW, Young JM, O'Neill BT. Spiropiperidine Sultam and Lactam Templates: Diastereoselective Overman Rearrangement and Metathesis followed by NH Arylation. J Org Chem 2017; 82:12246-12256. [PMID: 29096057 DOI: 10.1021/acs.joc.7b02096] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We report the diastereoselective synthesis of novel spiropiperidine templates for use in SAR studies of β-secretase (BACE) inhibitors and also as versatile ligands for other receptor types. The overall synthetic approach stems from chiral starting material benzyl (S)-2-methyl-4-oxopiperidine-1-carboxylate and employs an Overman rearrangement to control the stereochemistry at the quaternary center. This process is followed by a Grubbs metathesis to close a five-membered "top" ring to form an α,β-unsaturated lactam or an α,β-unsaturated sultam. We also demonstrate that this chemistry can accommodate additional substituents on the lactam/sultam ring and allows late stage sequential functionalization of the amine and amide nitrogens to rapidly produce diverse analogues.
Collapse
Affiliation(s)
- Luis A Martinez-Alsina
- Medicine Design, Medicinal Chemistry, Pfizer Worldwide Research and Development , 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - John C Murray
- Medicine Design, Medicinal Chemistry, Pfizer Worldwide Research and Development , 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Leanne M Buzon
- Medicine Design, Medicinal Chemistry, Pfizer Worldwide Research and Development , 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Mark W Bundesmann
- Medicine Design, Medicinal Chemistry, Pfizer Worldwide Research and Development , 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Joseph M Young
- Novartis Institute for BioMedical Research , 5300 Chiron Way, Emeryville, California 94608-2916, United States
| | - Brian T O'Neill
- Medicine Design, Medicinal Chemistry, Pfizer Worldwide Research and Development , 445 Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
4
|
Geoghegan K, Bode JW. Bespoke SnAP Reagents for the Synthesis of C-Substituted Spirocyclic and Bicyclic Saturated N-Heterocycles. Org Lett 2015; 17:1934-7. [DOI: 10.1021/acs.orglett.5b00618] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Kimberly Geoghegan
- Laboratorium für Organische Chemie, Department of Chemistry
and Applied Biosciences, ETH Zürich, Vladimir Prelog Weg 3, CH-8093 Zürich, Switzerland
| | - Jeffrey W. Bode
- Laboratorium für Organische Chemie, Department of Chemistry
and Applied Biosciences, ETH Zürich, Vladimir Prelog Weg 3, CH-8093 Zürich, Switzerland
| |
Collapse
|
5
|
Montuschi P, Ciabattoni G. Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends. J Med Chem 2015; 58:4131-64. [DOI: 10.1021/jm5013227] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Paolo Montuschi
- Department of Pharmacology,
Faculty of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito, 1, Rome, 00168, Italy
| | - Giovanni Ciabattoni
- Department of Pharmacology,
Faculty of Medicine, Catholic University of the Sacred Heart, Largo Francesco Vito, 1, Rome, 00168, Italy
| |
Collapse
|
6
|
Žukauskaitė A, Mangelinckx S, Callebaut G, Wybon C, Šačkus A, De Kimpe N. Synthesis of 1,5-diazaspiro[2.3]hexanes, a novel diazaspirocyclic system. Tetrahedron 2013. [DOI: 10.1016/j.tet.2013.02.065] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
7
|
Norman P. Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115? Expert Opin Ther Pat 2012; 22:1377-83. [PMID: 22917191 DOI: 10.1517/13543776.2012.718761] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
These two patent applications each claim combination formulations comprising a single dual-acting muscarinic antagonist/beta 2 agonist (MABA), as a free base or salt, with a second class of drug and the use of these formulations for the treatment of asthma and COPD. The two specified compounds are close analogues of each other and were originally disclosed in the same patent application. They are, respectively, 3-(2-chloro-3-((4-(2-ethylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)methyl)phenethoxy)-N-cyclopentyl-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b]{1,4] oxazin-8-yl)ethylamino)ethyl)propanamide and N-butyl-N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][l,4]oxazin-8-yl)ethylamino)ethyl)-3-(3-(2-(4-(2-isopropylthiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl)phenethoxy)propanamide.
Collapse
Affiliation(s)
- Peter Norman
- Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW,
| |
Collapse
|
8
|
Hughes AD, McNamara A, Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD. PROGRESS IN MEDICINAL CHEMISTRY 2012; 51:71-95. [PMID: 22520472 DOI: 10.1016/b978-0-12-396493-9.00003-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Affiliation(s)
- Adam D Hughes
- Department of Medicinal Chemistry, Theravance, Inc., South San Francisco, CA, USA
| | | | | |
Collapse
|
9
|
Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Future Med Chem 2011; 3:1623-34. [DOI: 10.4155/fmc.11.127] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
In 2002, the first long-acting muscarinic antagonist, tiotropium bromide (Spiriva®), was launched as a once-daily bronchodilating agent for the treatment of chronic obstructive pulmonary disease. Since then, there has been intense discovery research activity in this area and, currently, several alternative inhaled long-acting muscarinic antagonists are reported under clinical development by several pharmaceutical companies. This article will review the current inhaled development candidates, as well as literature reports of the most significant preclinical chemical series specifically designed as inhaled antimuscarinic agents.
Collapse
|
10
|
Parameswarappa SG, Pigge F. Synthesis of substituted 3,9-diazaspiro[5.5]undecanes via spirocyclization of pyridine substrates. Tetrahedron Lett 2011. [DOI: 10.1016/j.tetlet.2011.06.055] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
|